3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
4
Tumor-Agnostic
1
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasm Metastasis
1
Interventions
pembrolizumab
17
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
8
Paclitaxel
7
Biopsy
7
Nivolumab
6
atezolizumab
5
Surveys and Questionnaires
4
Standard of Care
4
Radiosurgery
4
Practice Guidelines as Topic
4
Pemetrexed
4
Oxaliplatin
4
Cyclophosphamide
4
Carboplatin
4
osimertinib
3
niraparib
3
durvalumab
3
cemiplimab
3
avelumab
3
Radiotherapy
3
Radiation
3
Leucovorin
3
Irinotecan
3
Ipilimumab
3
Interviews as Topic
3
Fluorouracil
3
trastuzumab deruxtecan
2
trametinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
AZD9833
×
Tumor-Agnostic
×
Clear all
NCT04214288
2025-11-20
SERENA-2
AstraZeneca
Phase 2
Active not recruiting
240 enrolled
16 charts